Nadofaragene Firadenovec Shows Durable Responses in NMIBC

Stephen Boorjian, MD, discusses the efficacy results of the phase II study intravesical nadofaragene firadenovec in patients with high-grade, Bacillus Calmette-Guerin unresponsive nonmuscle invasive bladder cancer, which he presented at the 2020 Genitourinary Cancer Symposium. 

Stephen Boorjian, MD, professor of Urology, Mayo Clinic, discusses the efficacy results of the phase III study intravesical nadofaragene firadenovec (Instilladrin) in patients with high-grade, Bacillus Calmette-Guerin unresponsive nonmuscle invasive bladder cancer (NMIBC), which he presented at the 2020 Genitourinary Cancer Symposium.

The primary finding from the study was that 53% of patients with carcinoma in situ achieved a complete response following treatment with nadofaragene firadenovec, meeting the primary end point of the study.

Another key finding of the study is that the responses observed in these patients were durable, Boorjian reports.

<< For more about the 2020 Genitourinary Cancer Symposium